FFP with Complete Screening (One Bag) at Chughtai Lab

FFP’s with Complete Screening (One Bag) at Chughtai Lab

Fresh Frozen Plasma (FFP) is a vital, life-saving blood component that contains the liquid portion of whole blood, separated and frozen rapidly to preserve its essential therapeutic properties. At Chughtai Lab, a premier diagnostic network in Pakistan, the FFP with Complete Screening (One Bag) service is designed to provide patients with the highest quality plasma that has undergone rigorous testing for transfusion-transmitted infections (TTIs). FFP is rich in all coagulation factors, albumin, globulins, and other crucial plasma proteins, making it an indispensable therapeutic agent in emergency medicine, critical care, and hematology. The complete screening process ensures that each bag of plasma is safe, sterile, and free from infectious pathogens, thereby minimizing the risk of transfusion-related complications and safeguarding patient health.

The preparation of FFP involves separating the plasma from cellular blood components, such as red blood cells and platelets, within eight hours of whole blood collection. This rapid separation and subsequent freezing at -18 degrees Celsius or colder are critical to maintaining the activity of labile clotting factors, particularly Factor V and Factor VIII. These factors are essential for the coagulation cascade, which stops bleeding and promotes wound healing. Chughtai Lab utilizes state-of-the-art automated component extractors and ultra-low temperature freezers to ensure that the physiological integrity of the plasma is fully preserved. By combining advanced technology with stringent quality control protocols, Chughtai Lab delivers a product that clinicians can trust in critical, life-or-death situations.

The clinical importance of FFP with Complete Screening cannot be overstated. It is primarily used to treat patients with multiple coagulation factor deficiencies, active hemorrhage, or those undergoing massive transfusion protocols. The diagnostic and therapeutic value of this service lies in its ability to rapidly restore hemostasis, prevent excessive blood loss, and support patients during complex surgical procedures. By ensuring that each bag undergoes comprehensive screening for major infectious diseases, Chughtai Lab provides a safe and reliable resource for hospitals and healthcare providers across Pakistan, including major cities like Lahore, Karachi, and Islamabad.

Clinical Procedure: What to Expect

Patient Preparation

Patient preparation for receiving or donating blood components like FFP is a meticulous process designed to ensure safety and compatibility. For recipients, the preparation involves several critical steps:

• ABO and Rh Blood Grouping: A blood sample must be drawn from the recipient to determine their exact blood group and Rh status. FFP must be compatible with the recipient’s red blood cells to prevent acute hemolytic transfusion reactions.
• Antibody Screening: The recipient’s serum is screened for atypical antibodies that could react with the transfused plasma.
• Informed Consent: The attending physician must explain the benefits, risks, and alternatives of the FFP transfusion, and obtain signed informed consent from the patient or their legal guardian.
• Intravenous Access: A patent, large-bore intravenous (IV) cannula (typically 18G or 20G) must be established to facilitate the smooth infusion of the plasma.
• Pre-Transfusion Vitals: Baseline vital signs, including temperature, blood pressure, heart rate, and respiratory rate, must be recorded immediately before the transfusion begins.

During the Procedure

The procedure for preparing and administering FFP involves a highly coordinated workflow between the laboratory and the clinical team:

• Blood Collection and Separation: Whole blood is collected from a healthy, thoroughly screened donor using sterile, single-use triple-bag systems. The blood is centrifuged under refrigerated conditions to separate the plasma from the cellular elements.
• Rapid Freezing: The separated plasma is transferred to a satellite bag and frozen to -18 degrees Celsius or colder within eight hours of collection to preserve labile coagulation factors.
• Infectious Disease Screening: A sample of the donor’s blood undergoes exhaustive screening using advanced Chemiluminescence Immunoassay (CLIA) or Nucleic Acid Testing (NAT) technologies. This screens for Hepatitis B, Hepatitis C, HIV, Syphilis, and Malaria.
• Storage and Inventory: Once cleared, the FFP bag is labeled with a unique barcode, blood group, expiration date, and screening status, and stored in temperature-monitored freezers.
• Thawing Process: Prior to transfusion, the FFP bag is thawed in a specialized, temperature-controlled water bath or dry defroster at 30 to 37 degrees Celsius. Thawing takes approximately 20 to 30 minutes.
• Transfusion Administration: The thawed FFP must be transfused immediately through a standard blood administration set with a 170-to-260-micron filter. The infusion should be completed within 4 hours of thawing to prevent bacterial growth and factor degradation.
• Monitoring: The patient is closely monitored by healthcare professionals, especially during the first 15 minutes of the transfusion, to detect any adverse reactions such as fever, chills, urticaria, or respiratory distress.

When is a FFP’s with Complete Screening (One Bag) Performed?

Management of Active Hemorrhage in Coagulopathy

Physicians request FFP with Complete Screening when a patient is experiencing active, severe bleeding associated with a documented coagulation factor deficiency. This is common in patients with severe liver disease, where the synthesis of clotting factors is severely impaired. Transfusing FFP helps replenish these essential proteins, enabling the body to form stable blood clots and arrest the hemorrhage effectively.

Urgent Reversal of Warfarin (Anticoagulant) Therapy

Patients on warfarin therapy who experience life-threatening bleeding or require emergency surgery need rapid reversal of the drug’s anticoagulant effects. Warfarin inhibits vitamin K-dependent clotting factors (Factors II, VII, IX, and X). FFP contains these factors in physiological concentrations, providing an immediate source of active clotting proteins to restore normal coagulation when specific prothrombin complex concentrates are unavailable.

Therapeutic Plasma Exchange (TPE)

In conditions such as Thrombotic Thrombocytopenic Purpura (TTP) or atypical Hemolytic Uremic Syndrome (aHUS), therapeutic plasma exchange is a critical intervention. During TPE, the patient’s abnormal plasma is removed and replaced with donor FFP. FFP serves as the replacement fluid because it supplies the missing ADAMTS13 enzyme and other essential proteins, while avoiding the depletion of coagulation factors during the apheresis procedure.

Correction of Isolated Coagulation Factor Deficiencies

While specific factor concentrates are preferred, FFP is indicated for the treatment of congenital or acquired deficiencies of clotting factors for which no specific concentrate is available. This includes deficiencies of Factor V, Factor XI, and Factor XVII. Transfusing FFP provides the necessary factors to maintain adequate hemostasis during invasive procedures or bleeding episodes.

Treatment of Disseminated Intravascular Coagulation (DIC)

Disseminated Intravascular Coagulation is a complex, life-threatening systemic process characterized by widespread microvascular thrombosis and subsequent consumption of platelets and clotting factors. In patients with acute DIC who are actively bleeding or at high risk of bleeding, FFP is administered to replenish the depleted coagulation factors and fibrinogen, helping to restore the body’s hemostatic balance.

What Does a FFP’s with Complete Screening (One Bag) Detect?

The complete screening process for a bag of Fresh Frozen Plasma at Chughtai Lab is designed to detect and verify a wide range of infectious markers, compatibility factors, and quality parameters to ensure maximum patient safety. The screening and quality control process detects and evaluates the following:

• Hepatitis B Surface Antigen (HBsAg): Detects active Hepatitis B infection in the donor.
• Antibodies to Hepatitis C Virus (Anti-HCV): Identifies exposure to or active infection with the Hepatitis C virus.
• Antibodies to Human Immunodeficiency Virus (Anti-HIV 1/2): Screens for the presence of HIV-1 and HIV-2 antibodies.
• HIV-1/2 Antigen (p24): Detects early-stage HIV infection before antibodies develop.
• Syphilis Antibodies (VDRL/TPHA): Screens for Treponema pallidum, the causative agent of syphilis.
• Malaria Parasite (MP): Detects Plasmodium species using high-sensitivity antigen tests or microscopic examination.
• ABO Blood Group Antigens: Identifies the presence of A and B antigens on red cells to determine the correct plasma group (A, B, AB, or O).
• Rh (D) Antigen Status: Determines whether the donor is Rh-positive or Rh-negative.
• Atypical Red Cell Antibodies: Screens for unexpected antibodies in the donor plasma that could react with recipient red cells.
• Total Protein Levels: Measures the concentration of plasma proteins to ensure nutritional and therapeutic quality.
• Albumin Concentration: Verifies adequate levels of albumin, which maintains oncotic pressure.
• Fibrinogen Levels (Factor I): Ensures sufficient fibrinogen content, critical for clot formation.
• Prothrombin Time (PT): Assesses the functional integrity of the extrinsic coagulation pathway in the plasma.
• Activated Partial Thromboplastin Time (aPTT): Evaluates the functional integrity of the intrinsic coagulation pathway.
• Factor V Activity: Verifies the preservation of this highly labile clotting factor.
• Factor VIII Activity: Measures the levels of Factor VIII to ensure therapeutic efficacy for hemophilia A or general coagulopathy.
• Factor IX Activity: Evaluates the presence of Factor IX, essential for the coagulation cascade.
• Factor XI Activity: Assesses the levels of Factor XI to ensure adequacy for deficient patients.
• Antithrombin III Levels: Measures this natural anticoagulant protein to ensure balanced plasma composition.
• Absence of Bacterial Contamination: Verifies that the plasma bag is free from aerobic and anaerobic bacterial growth.
• Absence of Visible Hemolysis: Detects any red or pink discoloration indicating red blood cell rupture during processing.
• Absence of Lipemia: Identifies a milky or turbid appearance caused by high lipid content, which can interfere with transfusion.
• Residual Red Blood Cell Count: Ensures that the plasma is virtually free of red blood cells to prevent alloimmunization.
• Residual White Blood Cell Count: Verifies the efficiency of leukoreduction filters, reducing the risk of febrile non-hemolytic transfusion reactions.
• Residual Platelet Count: Confirms that platelets have been successfully separated from the plasma.
• Plasma Volume Verification: Ensures the bag contains the standard therapeutic volume (typically 200 to 250 mL).
• Bag Integrity and Seal Quality: Detects any micro-leaks or defects in the plastic bag or tubing that could compromise sterility.
• Barcode and Labeling Accuracy: Verifies that all donor details, compatibility data, and expiration dates are correctly matched and traceable.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing rapid, accurate, and reliable diagnostic and blood banking services. For emergency cases requiring FFP, Chughtai Lab prioritizes cross-matching and screening to ensure that compatible plasma bags are prepared and released within the shortest possible timeframe, often within a few hours. The laboratory utilizes advanced Laboratory Information Management Systems (LIMS) to track the screening process from sample collection to final verification.

Patients, families, and healthcare providers can easily access screening reports and compatibility certificates online. Chughtai Lab offers multiple convenient digital platforms, including the official Chughtai Lab website and the user-friendly My Chughtai mobile application. Once the screening and cross-matching are complete, an automated SMS notification is sent to the registered mobile number with a direct link to download the PDF report. This seamless digital integration ensures that critical medical information is available instantly, facilitating prompt clinical decisions and timely patient care.

FFP’s with Complete Screening (One Bag) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
ABO / Rh Grouping	Compatible with recipient’s blood group	Incompatible blood group (risk of hemolytic reaction)
Hepatitis B Surface Antigen (HBsAg)	Non-Reactive (Negative)	Reactive (Positive) – Unsafe for transfusion
Anti-HCV Antibodies	Non-Reactive (Negative)	Reactive (Positive) – Unsafe for transfusion
Anti-HIV 1/2 Antibodies	Non-Reactive (Negative)	Reactive (Positive) – Unsafe for transfusion
Syphilis (VDRL/TPHA)	Non-Reactive (Negative)	Reactive (Positive) – Unsafe for transfusion
Malaria Parasite (MP)	Not Detected (Negative)	Detected (Positive) – Unsafe for transfusion
Coagulation Factor Activity (V & VIII)	Preserved activity (>70% of normal)	Reduced activity due to improper storage or thawing
Visual Appearance & Volume	Clear, straw-colored liquid; 200-250 mL	Hemolyzed (pink/red), lipemic (milky), or inadequate volume

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for FFP’s with Complete Screening (One Bag)?

• ISO 15189 Certified Laboratories: Chughtai Lab adheres to stringent international quality standards for diagnostic accuracy and safety.
• College of American Pathologists (CAP) Proficiency: Participates in rigorous external quality assurance programs to maintain world-class testing standards.
• State-of-the-Art Blood Banking: Equipped with advanced automated component separators and ultra-low temperature storage freezers.
• Highly Qualified Hematologists: Supervised by experienced consultant pathologists and hematologists specializing in transfusion medicine.
• Strict Cold Chain Maintenance: Ensures that FFP is stored and transported under continuous temperature monitoring to preserve clotting factors.
• 24/7 Availability: Blood bank services are operational round-the-clock to cater to emergency medical and surgical requirements.
• Convenient Digital Access: Quick and easy report retrieval through the My Chughtai App and official online portal.
• Nationwide Network: A vast network of collection centers and hospital labs across Pakistan, ensuring accessibility and prompt service.